Staar Surgical Company
Open
$28.30
Prev. Close
$28.33
High
$28.40
Low
$28.26
Market Snapshot
$1.4B
-66.8
-0.42
$313.9M
921
STAAR Surgical Co. engages in the design, development, manufacture, and sale of ophthalmic surgical products. The company is headquartered in Monrovia California, California and currently employs 957 full-time employees. The firm markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The firm's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). The company also market and sell an ICL lens to treat hyperopia (farsightedness), called Visian ICL. The company makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company’s principal products are ICLs used in refractive surgery, including its EVO family of lenses.
Staar Surgical Company reported a remarkable 120% revenue increase in Q1, prompting discussions about the sustainability of such rapid growth in the ophthalmic industry.
STAAR Surgical Co. engages in the design, development, manufacture, and sale of ophthalmic surgical products. The company is headquartered in Monrovia California, California and currently employs 957 full-time employees. The firm markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The firm's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). The company also market and sell an ICL lens to treat hyperopia (farsightedness), called Visian ICL. The company makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company’s principal products are ICLs used in refractive surgery, including its EVO family of lenses.
Recently from Cashu

STAAR Surgical Reports 120% Revenue Growth, Signaling Strong Market Position and Future Potential
STAAR Surgical Company (Ticker: STAA) achieves remarkable revenue growth, signaling potential for continued success in the specialty medical device sector. The company reports a striking 120% increase…

Staar Surgical Company Reports 119.6% Revenue Growth Driven by EVO ICL Demand in China
Staar Surgical Company (Ticker: STAA) demonstrates significant growth in its first-quarter financial performance, reflecting a strategic focus on innovation and market expansion. The company's latest…
STAAR 2.0: Transforming AI Compliance for Staar Surgical and Other Companies
Advancing Compliance in AI: The Launch of STAAR 2.0 In the rapidly evolving landscape of artificial intelligence (AI), legal compliance remains paramount. Staar Surgical Company, as a key player in th…
Debevoise Launches STAAR 2.0: A New AI Compliance Tool for Legal Teams
Navigating AI Compliance: The Launch of STAAR 2.0 by Debevoise & Plimpton In a notable advancement for the legal technology landscape, Debevoise & Plimpton LLP unveils STAAR 2.0, an enhanced version o…